Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial-Reference-Cited by-同舟云学术

Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial

Published:2006-02-20 Issue:1 Volume:41 Page:70-76
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Sakamoto Hiroki,Kitano Masayuki,Suetomi Yoichirou,Takeyama Yoshifumi,Ohyanagi Harumasa,Nakai Takuya,Yasuda Chikao,Kudo Masatoshi

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-005-1724-7.pdf

Reference24 articles.

1. Ministry of Health, Labour and Welfare Statistics and Information. 2001 vital statistics of Japan. http://wwwdbtk.mhlw.go.jp/toukei/youran/data13/1-35.htm (in Japanese)

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies;Cancer Letters;2023-10

2. Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial;JGH Open;2023-09

3. The Patient’s Requirements;Intestinal Failure;2023

4. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients;International Immunopharmacology;2022-05

5. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network;Dermatology;2021-09-02